{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-003575","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.353389+00:00","generated_at":"2026-05-16T03:34:42.283960+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phio reports 85% pathological response in highest dose cohort of PH-762 Phase 1b trial; no serious adverse events","bullets":["No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.","85% pathological response (6/7 patients) in final cohort; 4 of 6 responders had complete tumor clearance.","Overall response rate of 65% for squamous cell carcinomas (13/20 pathologic responders, including 9 complete).","FDA submission for next-step guidance targeted for Q2 2026; cGMP manufacturing expected in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-003575","json":"https://secwatch.observer/filing/0001437749-26-003575.json","markdown":"https://secwatch.observer/filing/0001437749-26-003575.md","text":"https://secwatch.observer/filing/0001437749-26-003575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926003575/0001437749-26-003575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926003575/phio20260206_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:34:42.283960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}